TY - JOUR AU - Siegel, R. L. AU - Miller, K. D. AU - Jemal, A. PY - 2019 DA - 2019// TI - Cancer statistics, 2019 JO - CA. VL - 69 ID - Siegel2019 ER - TY - JOUR AU - Narod, S. PY - 2016 DA - 2016// TI - Can advanced-stage ovarian cancer be cured? JO - Nat Rev Clin Oncol VL - 13 UR - https://doi.org/10.1038/nrclinonc.2015.224 DO - 10.1038/nrclinonc.2015.224 ID - Narod2016 ER - TY - JOUR AU - Bowtell, D. D. AU - Bohm, S. AU - Ahmed, A. A. PY - 2015 DA - 2015// TI - Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer JO - Nat Rev Cancer VL - 15 UR - https://doi.org/10.1038/nrc4019 DO - 10.1038/nrc4019 ID - Bowtell2015 ER - TY - JOUR AU - Jayson, G. C. AU - Kohn, E. C. AU - Kitchener, H. C. PY - 2014 DA - 2014// TI - Ovarian cancer JO - Lancet VL - 384 UR - https://doi.org/10.1016/S0140-6736(13)62146-7 DO - 10.1016/S0140-6736(13)62146-7 ID - Jayson2014 ER - TY - JOUR AU - Koppenol, W. H. AU - Bounds, P. L. AU - Dang, C. V. PY - 2011 DA - 2011// TI - Otto Warburg's contributions to current concepts of cancer metabolism JO - Nat Rev Cancer VL - 11 UR - https://doi.org/10.1038/nrc3038 DO - 10.1038/nrc3038 ID - Koppenol2011 ER - TY - JOUR AU - Vander Heiden, M. G. AU - DeBerardinis, R. J. PY - 2017 DA - 2017// TI - Understanding the Intersections between metabolism and cancer biology JO - Cell VL - 168 UR - https://doi.org/10.1016/j.cell.2016.12.039 DO - 10.1016/j.cell.2016.12.039 ID - Vander Heiden2017 ER - TY - JOUR AU - Sullivan, L. B. AU - Gui, D. Y. AU - Vander Heiden, M. G. PY - 2016 DA - 2016// TI - Altered metabolite levels in cancer: implications for tumour biology and cancer therapy JO - Nat Rev Cancer VL - 16 UR - https://doi.org/10.1038/nrc.2016.85 DO - 10.1038/nrc.2016.85 ID - Sullivan2016 ER - TY - JOUR AU - Luengo, A. AU - Gui, D. Y. AU - Vander Heiden, M. G. PY - 2017 DA - 2017// TI - Targeting metabolism for cancer therapy JO - Cell Chem Biol VL - 24 UR - https://doi.org/10.1016/j.chembiol.2017.08.028 DO - 10.1016/j.chembiol.2017.08.028 ID - Luengo2017 ER - TY - JOUR AU - Xu, S. AU - Herschman, H. R. PY - 2019 DA - 2019// TI - A tumor agnostic therapeutic strategy for Hexokinase 1-Null/Hexokinase 2-positive cancers JO - Can Res VL - 79 UR - https://doi.org/10.1158/0008-5472.CAN-19-1789 DO - 10.1158/0008-5472.CAN-19-1789 ID - Xu2019 ER - TY - JOUR AU - Mathupala, S. P. AU - Ko, Y. H. AU - Pedersen, P. L. PY - 2006 DA - 2006// TI - Hexokinase II: cancer's double-edged sword acting as both facilitator and gatekeeper of malignancy when bound to mitochondria JO - Oncogene VL - 25 UR - https://doi.org/10.1038/sj.onc.1209603 DO - 10.1038/sj.onc.1209603 ID - Mathupala2006 ER - TY - JOUR AU - Patra, K. C. AU - Wang, Q. AU - Bhaskar, P. T. PY - 2013 DA - 2013// TI - Hexokinase 2 is required for tumor initiation and maintenance and its systemic deletion is therapeutic in mouse models of cancer JO - Cancer Cell VL - 24 UR - https://doi.org/10.1016/j.ccr.2013.06.014 DO - 10.1016/j.ccr.2013.06.014 ID - Patra2013 ER - TY - JOUR AU - DeWaal, D. AU - Nogueira, V. AU - Terry, A. R. PY - 2018 DA - 2018// TI - Hexokinase-2 depletion inhibits glycolysis and induces oxidative phosphorylation in hepatocellular carcinoma and sensitizes to metformin JO - Nature Communicat VL - 9 UR - https://doi.org/10.1038/s41467-017-02733-4 DO - 10.1038/s41467-017-02733-4 ID - DeWaal2018 ER - TY - JOUR AU - Ha, J. H. AU - Radhakrishnan, R. AU - Jayaraman, M. PY - 2018 DA - 2018// TI - LPA induces metabolic reprogramming in ovarian cancer via a pseudohypoxic response JO - Can Res VL - 78 UR - https://doi.org/10.1158/0008-5472.CAN-17-1624 DO - 10.1158/0008-5472.CAN-17-1624 ID - Ha2018 ER - TY - JOUR AU - Xu, S. AU - Zhou, T. AU - Doh, H. M. PY - 2019 DA - 2019// TI - An HK2 antisense oligonucleotide induces synthetic lethality in HK1(-)HK2(+) multiple myeloma JO - Can Res VL - 79 UR - https://doi.org/10.1158/0008-5472.CAN-18-2799 DO - 10.1158/0008-5472.CAN-18-2799 ID - Xu2019 ER - TY - JOUR AU - Suh, D. H. AU - Kim, M. A. AU - Kim, H. PY - 2014 DA - 2014// TI - Association of overexpression of hexokinase II with chemoresistance in epithelial ovarian cancer JO - Clin Exp Med VL - 14 UR - https://doi.org/10.1007/s10238-013-0250-9 DO - 10.1007/s10238-013-0250-9 ID - Suh2014 ER - TY - JOUR AU - Xintaropoulou, C. AU - Ward, C. AU - Wise, A. PY - 2018 DA - 2018// TI - Expression of glycolytic enzymes in ovarian cancers and evaluation of the glycolytic pathway as a strategy for ovarian cancer treatment JO - BMC Cancer VL - 18 UR - https://doi.org/10.1186/s12885-018-4521-4 DO - 10.1186/s12885-018-4521-4 ID - Xintaropoulou2018 ER - TY - JOUR AU - Siu, M. K. Y. AU - Jiang, Y. X. AU - Wang, J. J. PY - 2019 DA - 2019// TI - Hexokinase 2 Regulates Ovarian Cancer Cell Migration, Invasion and Stemness via FAK/ERK1/2/MMP9/NANOG/SOX9 Signaling Cascades JO - Cancers. VL - 11 UR - https://doi.org/10.3390/cancers11060813 DO - 10.3390/cancers11060813 ID - Siu2019 ER - TY - JOUR AU - Krasnov, G. S. AU - Dmitriev, A. A. AU - Lakunina, V. A. PY - 2013 DA - 2013// TI - Targeting VDAC-bound hexokinase II: a promising approach for concomitant anti-cancer therapy JO - Expert Opin Therapeutic Targets VL - 17 UR - https://doi.org/10.1517/14728222.2013.833607 DO - 10.1517/14728222.2013.833607 ID - Krasnov2013 ER - TY - JOUR AU - Shi, J. AU - Kantoff, P. W. AU - Wooster, R. PY - 2017 DA - 2017// TI - Cancer nanomedicine: progress, challenges and opportunities JO - Nat Rev Cancer VL - 17 UR - https://doi.org/10.1038/nrc.2016.108 DO - 10.1038/nrc.2016.108 ID - Shi2017 ER - TY - JOUR AU - Lorenzo, G. AU - Ricci, G. AU - Severini, G. M. PY - 2018 DA - 2018// TI - Imaging and therapy of ovarian cancer: clinical application of nanoparticles and future perspectives JO - Theranostics VL - 8 UR - https://doi.org/10.7150/thno.26345 DO - 10.7150/thno.26345 ID - Lorenzo2018 ER - TY - JOUR AU - Smith, R. J. AU - Beck, R. W. AU - Prevette, L. E. PY - 2015 DA - 2015// TI - Impact of molecular weight and degree of conjugation on the thermodynamics of DNA complexation and stability of polyethylenimine-graft-poly(ethylene glycol) copolymers JO - Biophys Chem VL - 203–204 UR - https://doi.org/10.1016/j.bpc.2015.04.005 DO - 10.1016/j.bpc.2015.04.005 ID - Smith2015 ER - TY - JOUR AU - Aghamiri, S. AU - Mehrjardi, K. F. AU - Shabani, S. PY - 2019 DA - 2019// TI - Nanoparticle-siRNA: a potential strategy for ovarian cancer therapy? JO - Nanomedicine VL - 14 UR - https://doi.org/10.2217/nnm-2018-0379 DO - 10.2217/nnm-2018-0379 ID - Aghamiri2019 ER - TY - JOUR AU - Papadimitriou, K. AU - Kountourakis, P. AU - Kottorou, A. E. PY - 2016 DA - 2016// TI - Follicle-stimulating hormone receptor (FSHR): a promising tool in oncology? JO - Mol Diagn Therapy VL - 20 UR - https://doi.org/10.1007/s40291-016-0218-z DO - 10.1007/s40291-016-0218-z ID - Papadimitriou2016 ER - TY - JOUR AU - Perales-Puchalt, A. AU - Svoronos, N. AU - Rutkowski, M. R. PY - 2017 DA - 2017// TI - Follicle-stimulating hormone receptor is expressed by most ovarian cancer subtypes and is a safe and effective immunotherapeutic target JO - Clin Cancer Res VL - 23 UR - https://doi.org/10.1158/1078-0432.CCR-16-0492 DO - 10.1158/1078-0432.CCR-16-0492 ID - Perales-Puchalt2017 ER - TY - JOUR AU - Zhang, X. Y. AU - Chen, J. AU - Zheng, Y. F. PY - 2009 DA - 2009// TI - Follicle-stimulating hormone peptide can facilitate paclitaxel nanoparticles to target ovarian carcinoma in vivo JO - Can Res VL - 69 UR - https://doi.org/10.1158/0008-5472.CAN-08-4721 DO - 10.1158/0008-5472.CAN-08-4721 ID - Zhang2009 ER - TY - JOUR AU - Feng, Z. AU - Wen, H. AU - Bi, R. PY - 2016 DA - 2016// TI - A clinically applicable molecular classification for high-grade serous ovarian cancer based on hormone receptor expression JO - Sci Rep VL - 6 UR - https://doi.org/10.1038/srep25408 DO - 10.1038/srep25408 ID - Feng2016 ER - TY - JOUR AU - Wei, S. AU - Lai, L. AU - Yang, J. PY - 2018 DA - 2018// TI - Expression levels of follicle-stimulating hormone receptor and implication in diagnostic and therapeutic strategy of ovarian cancer JO - Oncol Res Treat VL - 41 UR - https://doi.org/10.1159/000490810 DO - 10.1159/000490810 ID - Wei2018 ER - TY - JOUR AU - Zhang, M. AU - Zhang, M. AU - Wang, J. PY - 2018 DA - 2018// TI - Retro-inverso follicle-stimulating hormone peptide-mediated polyethylenimine complexes for targeted ovarian cancer gene therapy JO - Drug Deliv VL - 25 UR - https://doi.org/10.1080/10717544.2018.1461956 DO - 10.1080/10717544.2018.1461956 ID - Zhang2018 ER - TY - JOUR AU - Urbanska, K. AU - Stashwick, C. AU - Poussin, M. PY - 2015 DA - 2015// TI - Follicle-stimulating hormone receptor as a target in the redirected t-cell therapy for cancer JO - Cancer Immunol Res VL - 3 UR - https://doi.org/10.1158/2326-6066.CIR-15-0047 DO - 10.1158/2326-6066.CIR-15-0047 ID - Urbanska2015 ER - TY - JOUR AU - Santa Coloma, T. A. AU - Dattatreyamurty, B. AU - Reichert, L. E. PY - 1990 DA - 1990// TI - A synthetic peptide corresponding to human FSH beta-subunit 33–53 binds to FSH receptor, stimulates basal estradiol biosynthesis, and is a partial antagonist of FSH JO - Biochemistry VL - 29 UR - https://doi.org/10.1021/bi00457a015 DO - 10.1021/bi00457a015 ID - Santa Coloma1990 ER - TY - JOUR AU - Rai, J. PY - 2019 DA - 2019// TI - Peptide and protein mimetics by retro and retroinverso analogs JO - Chem Biol Drug Des VL - 93 UR - https://doi.org/10.1111/cbdd.13472 DO - 10.1111/cbdd.13472 ID - Rai2019 ER - TY - JOUR AU - Vaissiere, A. AU - Aldrian, G. AU - Konate, K. PY - 2017 DA - 2017// TI - A retro-inverso cell-penetrating peptide for siRNA delivery JO - J Nanobiotechnol VL - 15 UR - https://doi.org/10.1186/s12951-017-0269-2 DO - 10.1186/s12951-017-0269-2 ID - Vaissiere2017 ER - TY - JOUR AU - Zakeri, A. AU - Kouhbanani, M. A. J. AU - Beheshtkhoo, N. PY - 2018 DA - 2018// TI - Polyethylenimine-based nanocarriers in co-delivery of drug and gene: a developing horizon JO - Nano Rev Exp VL - 9 UR - https://doi.org/10.1080/20022727.2018.1488497 DO - 10.1080/20022727.2018.1488497 ID - Zakeri2018 ER - TY - JOUR AU - Kullberg, M. AU - McCarthy, R. AU - Anchordoquy, T. J. PY - 2013 DA - 2013// TI - Systemic tumor-specific gene delivery JO - J Control Release VL - 172 UR - https://doi.org/10.1016/j.jconrel.2013.08.300 DO - 10.1016/j.jconrel.2013.08.300 ID - Kullberg2013 ER - TY - JOUR AU - Vander Heiden, M. G. AU - Cantley, L. C. AU - Thompson, C. B. PY - 2009 DA - 2009// TI - Understanding the Warburg effect: the metabolic requirements of cell proliferation JO - Science VL - 324 UR - https://doi.org/10.1126/science.1160809 DO - 10.1126/science.1160809 ID - Vander Heiden2009 ER - TY - JOUR AU - Butler, E. B. AU - Zhao, Y. AU - Munoz-Pinedo, C. PY - 2013 DA - 2013// TI - Stalling the engine of resistance: targeting cancer metabolism to overcome therapeutic resistance JO - Can Res VL - 73 UR - https://doi.org/10.1158/0008-5472.CAN-12-3009 DO - 10.1158/0008-5472.CAN-12-3009 ID - Butler2013 ER - TY - JOUR AU - Caneba, C. A. AU - Bellance, N. AU - Yang, L. PY - 2012 DA - 2012// TI - Pyruvate uptake is increased in highly invasive ovarian cancer cells under anoikis conditions for anaplerosis, mitochondrial function, and migration JO - Am J Physiol Endocrinol Metab VL - 303 UR - https://doi.org/10.1152/ajpendo.00151.2012 DO - 10.1152/ajpendo.00151.2012 ID - Caneba2012 ER - TY - JOUR AU - Fabian, C. AU - Koetz, L. AU - Favaro, E. PY - 2012 DA - 2012// TI - Protein profiles in human ovarian cancer cell lines correspond to their metabolic activity and to metabolic profiles of respective tumor xenografts JO - FEBS J VL - 279 UR - https://doi.org/10.1111/j.1742-4658.2012.08479.x DO - 10.1111/j.1742-4658.2012.08479.x ID - Fabian2012 ER - TY - JOUR AU - Wolf, A. AU - Agnihotri, S. AU - Micallef, J. PY - 2011 DA - 2011// TI - Hexokinase 2 is a key mediator of aerobic glycolysis and promotes tumor growth in human glioblastoma multiforme JO - J Exp Med VL - 208 UR - https://doi.org/10.1084/jem.20101470 DO - 10.1084/jem.20101470 ID - Wolf2011 ER - TY - JOUR AU - Faubert, B. AU - Li, K. Y. AU - Cai, L. PY - 2017 DA - 2017// TI - Lactate Metabolism in Human Lung Tumors JO - Cell VL - 171 UR - https://doi.org/10.1016/j.cell.2017.09.019 DO - 10.1016/j.cell.2017.09.019 ID - Faubert2017 ER - TY - JOUR AU - Hui, S. AU - Ghergurovich, J. M. AU - Morscher, R. J. PY - 2017 DA - 2017// TI - Glucose feeds the TCA cycle via circulating lactate JO - Nature VL - 551 UR - https://doi.org/10.1038/nature24057 DO - 10.1038/nature24057 ID - Hui2017 ER - TY - JOUR AU - San-Millan, I. AU - Brooks, G. A. PY - 2017 DA - 2017// TI - Reexamining cancer metabolism: lactate production for carcinogenesis could be the purpose and explanation of the Warburg Effect JO - Carcinogenesis VL - 38 ID - San-Millan2017 ER - TY - JOUR AU - Hirschhaeuser, F. AU - Sattler, U. G. AU - Mueller-Klieser, W. PY - 2011 DA - 2011// TI - Lactate: a metabolic key player in cancer JO - Can Res VL - 71 UR - https://doi.org/10.1158/0008-5472.CAN-11-1457 DO - 10.1158/0008-5472.CAN-11-1457 ID - Hirschhaeuser2011 ER - TY - JOUR AU - Goetze, K. AU - Walenta, S. AU - Ksiazkiewicz, M. PY - 2011 DA - 2011// TI - Lactate enhances motility of tumor cells and inhibits monocyte migration and cytokine release JO - Int J Oncol VL - 39 ID - Goetze2011 ER - TY - JOUR AU - Chakraborty, P. K. AU - Mustafi, S. B. AU - Xiong, X. PY - 2017 DA - 2017// TI - MICU1 drives glycolysis and chemoresistance in ovarian cancer JO - Nat Commun VL - 8 UR - https://doi.org/10.1038/ncomms14634 DO - 10.1038/ncomms14634 ID - Chakraborty2017 ER - TY - JOUR AU - Zhao, Y. AU - Butler, E. B. AU - Tan, M. PY - 2013 DA - 2013// TI - Targeting cellular metabolism to improve cancer therapeutics JO - Cell Death Dis VL - 4 UR - https://doi.org/10.1038/cddis.2013.60 DO - 10.1038/cddis.2013.60 ID - Zhao2013 ER - TY - JOUR AU - Zhou, Y. AU - Tozzi, F. AU - Chen, J. PY - 2012 DA - 2012// TI - Intracellular ATP levels are a pivotal determinant of chemoresistance in colon cancer cells JO - Can Res VL - 72 UR - https://doi.org/10.1158/0008-5472.CAN-11-1674 DO - 10.1158/0008-5472.CAN-11-1674 ID - Zhou2012 ER - TY - JOUR AU - Vartanian, A. AU - Agnihotri, S. AU - Wilson, M. R. PY - 2016 DA - 2016// TI - Targeting hexokinase 2 enhances response to radio-chemotherapy in glioblastoma JO - Oncotarget VL - 7 UR - https://doi.org/10.18632/oncotarget.11680 DO - 10.18632/oncotarget.11680 ID - Vartanian2016 ER - TY - JOUR AU - Zhang, Y. AU - Liu, Y. AU - Xu, X. PY - 2018 DA - 2018// TI - Knockdown of LncRNA-UCA1 suppresses chemoresistance of pediatric AML by inhibiting glycolysis through the microRNA-125a/hexokinase 2 pathway JO - J Cell Biochem VL - 119 UR - https://doi.org/10.1002/jcb.26899 DO - 10.1002/jcb.26899 ID - Zhang2018 ER - TY - JOUR AU - Shi, T. AU - Ma, Y. AU - Cao, L. PY - 2019 DA - 2019// TI - B7–H3 promotes aerobic glycolysis and chemoresistance in colorectal cancer cells by regulating HK2 JO - Cell Death Dis VL - 10 UR - https://doi.org/10.1038/s41419-019-1549-6 DO - 10.1038/s41419-019-1549-6 ID - Shi2019 ER -